CUBT — Curative Biotechnology Income Statement
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
- $10.02m
- $10.87m
Annual income statement for Curative Biotechnology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 0 | 0 | 0 |
| Cost of Revenue | |||
| Gross Profit | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Depreciation and Amortization | |||
| Unusual Expense / Income | |||
| Total Operating Expenses | -0.223 | 4.64 | 5.16 |
| Operating Profit | 0.223 | -4.64 | -5.16 |
| Total Net Non Operating Interest Income / Expense | |||
| Net Income Before Taxes | 0.207 | -4.67 | -5.34 |
| Net Income After Taxes | 0.207 | -4.67 | -5.34 |
| Net Income Before Extraordinary Items | |||
| Net Income | 0.207 | -4.67 | -5.34 |
| Adjustments to Net Income | |||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | 0.207 | -4.67 | -18.8 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -0 | -0.008 | -0.033 |